BriaCell Therapeutics Corp. (NASDAQ: BCTX) completed manufacturing clinical supplies of Bria-PROS+, its immunotherapy candidate for prostate cancer, according to a company statement.

The Philadelphia and Vancouver-based biotechnology company plans to initiate a Phase 1/2a clinical study for the treatment in the coming months. Bria-PROS+ is described as a personalized, off-the-shelf, cell-based immunotherapy designed for prostate cancer patients.

In August 2025, BriaCell received a $2 million non-dilutive grant from the US National Cancer Institute to support manufacturing and clinical evaluation of Bria-PROS+.

"We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next generation personalized immunotherapy candidate for prostate cancer," stated Dr. William V. Williams, BriaCell's President and CEO. "The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favorable safety profile."

According to the company's recent presentation at the American Association for Cancer Research conference, Bria-PROS+ demonstrated activation of adaptive and innate immunity, including activation of T-cells, dendritic cells and natural killer cells in preclinical studies.

The therapy is based on the same platform as Bria-BRES+, BriaCell's breast cancer immunotherapy candidate, which recently received FDA clearance of its Investigational New Drug application.

BriaCell previously reported that in its breast cancer program, a 78-year-old patient with advanced metastatic breast cancer achieved complete resolution of a lung metastasis following treatment with Bria-OTS. The response was maintained through 11 months of follow-up.